IP Group is an investment company that helps to create, build and support IP-based companies internationally. The group focuses on companies that meaningfully contribute to a healthier, tech-enriched, regenerative future. IP Group is mostly active in the UK, with an international footprint through investment platforms in Australia, New Zealand and the US. Below we highlight four key reasons why IP Group represents an exciting investment case: IP Group offers access to potentially disruptive innovations. IP Group’s management sees a strong exit pipeline ahead. IP Group may generate significant income from the IP it owns. Scale-up capital to support companies in their rapid growth phase. For more information on IP Group, please see our website.

In this interview, IP Group’s CEO, Greg Smith, highlights the potentially transformational implications of Pfizer’s acquisition of Metsera (for up to $7.3bn, of which $4.9bn is in upfront cash), whose MET-097 anti-obesity drug is progressing through Phase II. IP Group is entitled to low single‑digit royalties from a number of Metsera compounds, including MET‑097. EvaluatePharma forecasts that MET-097 could generate $9.2bn in non-risk-adjusted revenue by 2032, implying significant royalty streams to IP Group if commercialisation is successful. Greg reiterates confidence in management’s target of achieving at least £250m of exits by end‑2027 (excluding Oxford Nanopore), citing Monolith’s sale to CoreWeave and Hinge Health’s NYSE IPO (where IP Group achieved roughly a 50x return) as evidence. Greg also discusses progress on securing third‑party capital through UK pension funds and Mansion House initiatives, with management expecting to announce a new mandate by full‑year results, while highlighting portfolio momentum across AI, genomics, quantum and cleantech sectors.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.

In this interview, IP Group’s CEO, Greg Smith, highlights the potentially transformational implications of Pfizer’s acquisition of Metsera (for up to $7.3bn, of which $4.9bn is in upfront cash), whose MET-097 anti-obesity drug is progressing through Phase II. IP Group is entitled to low single‑digit royalties from a number of Metsera compounds, including MET‑097. EvaluatePharma forecasts that MET-097 could generate $9.2bn in non-risk-adjusted revenue by 2032, implying significant royalty streams to IP Group if commercialisation is successful. Greg reiterates confidence in management’s target of achieving at least £250m of exits by end‑2027 (excluding Oxford Nanopore), citing Monolith’s sale to CoreWeave and Hinge Health’s NYSE IPO (where IP Group achieved roughly a 50x return) as evidence. Greg also discusses progress on securing third‑party capital through UK pension funds and Mansion House initiatives, with management expecting to announce a new mandate by full‑year results, while highlighting portfolio momentum across AI, genomics, quantum and cleantech sectors. IP Group helps to create, build and support IP-based companies internationally. It focuses on companies that meaningfully contribute to regenerative (renewable), healthier (life sciences) and tech-enriched (deep tech) futures.